Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Am J Transplant. 2015 Apr 30;15(8):2223–2230. doi: 10.1111/ajt.13281

Figure 2.

Figure 2

A Unadjusted survival analysis comparing survival after re-LTx for BOS with rCLAD demonstrating a significantly worse survival in rCLAD patients compared to BOS patients. The p-value shown is the result of an univariate log-rank test.

B Unadjusted, overall freedom from CLAD analysis (conditional on 90-days survival), which demonstrates a significant difference between BOS and rCLAD. However, rCLAD patients develop CLAD earlier than BOS patients. The p-value shown is the result of a univariate log-rank test.

HHS Vulnerability Disclosure